In patients w/ ATTR-CM on TTR stabilizers, mortality did not differ among those w/ 99mTc-PYP visual grades 2 & 3, but higher NAC stage & worse NYHA class remained strong & independent predictors of mortality. #cvnuc
Read now👉https://t.co/eDZYJWyWfY
Tracking response to therapy in #Amyloidosis, with #CVNuc Dr. Shilpa Vijayakumar #ASNC2025@MyASNC 2/2🔋
👉The decrease in CARI uptake seems to be indicative of the molecule stabilization rather that regression ♥️
At today‘s @MyASNC webinar around the 🌎👉🏼 Dr. Elisa Milan presents an interesting case with dual pathology with cardiac amyloidosis and aortic stenosis:
✏️ TAVR should not be withheld!
✏️ Always exclude AL amyloidosis with serum & urine immunofixation and free light chains
124I-evuzamitide PET/CT accurately identifies cardiac light chain & TTR #amyloidosis, excludes amyloid in healthy controls, & may be better than 18F-florbetapir for TTR quantification. https://t.co/Eyea3fe6Cf
#ThinkPET#cvPET#JACCIMG@SVijayakumarMD@DorbalaSharmila
Check out this exciting new investigation into the performance of AT-01 (124I-evuzamitide) PET/CT and a comparison to 18F florbetapir by @DorbalaSharmila@sarahcud et al.
https://t.co/SK3B02tYNS
#CardioTwitter#CVNuc
What an amazing group of people that I have had the privilege to train with over the past 2 years! @BWHCVImaging 10th annual research day led by Dr. @mdicarli! We loved having Dr. Susan Cheng from @CedarsSinai & are so grateful for the time she took out to meet & mentor fellows!